Navigation Links
Liposome-hydrogel hybrids: No toil, no trouble for stronger bubbles

People have been combining materials to bring forth the best properties of both ever since copper and tin were merged to start the Bronze Age. In the latest successful merger, researchers at the National Institute of Standards and Technology (NIST), the University of Maryland (UM) and the U.S. Food and Drug Administration (FDA) have developed a method to combine two substances that individually have generated interest for their potential biomedical applications: a phospholipid membrane "bubble" called a liposome and particles of hydrogel, a water-filled network of polymer chains. The combination forms a hybrid nanoscale (billionth of a meter) particle that may one day travel directly to specific cells such as tumors, pass easily though the target's cell membrane, and then slowly release a drug payload.

In a recent paper in the journal Langmuir*, the research team reviewed how liposomes and hydrogel nanoparticles have individual advantages and disadvantages for drug delivery. While liposomes have useful surface properties that allow them to target specific cells and pass through membranes, they can rupture if the surrounding environment changes. Hydrogel nanoparticles are more stable and possess controlled release capabilities to tune the dosage of a drug over time, but are prone to degradation and clumping. The researchers' goal was to engineer nanoparticles incorporating both components to utilize the strengths of each material while compensating for their weaknesses.

To manufacture their liposome-hydrogel hybrid vesicles, the researchers adapted a NIST-UM technique known as COMMAND for COntrolled Microfluidic Mixing And Nanoparticle Determination that uses a microscopic fluidic (microfluidic) device (see "NIST, Maryland Researchers COMMAND a Better Class of Liposomes" in NIST Tech Beat, April 27, 2010). In the new work, phospholipid molecules are dissolved in isopropyl alcohol and fed via a tiny (21 micrometers in diameter, or three times the size of a yeast cell) inlet channel into a "mixer" channel, then "focused" into a fluid jet by a water-based solution added through two side channels. Hydrogel precursor molecules are mixed in with the focusing fluid.

As the components blend together at the interfaces of the fluid streams, the phospholipid molecules self-assemble into nanoscale vesicles of controlled size and trap the monomers in solution inside. The newly formed vesicles then are irradiated with ultraviolet light to polymerize the hydrogel precursors they carry into a solid gel made up of cross-linked chains. These chains give strength to the vesicles while permitting them to retain the spherical shape of the liposome envelope (which, in turn, would facilitate passage through a cell membrane).

To turn the liposome-hydrogel hybrid vesicles into cellular delivery vehicles, a drug or other cargo would be added to the focusing fluid during production.


Contact: Michael E. Newman
National Institute of Standards and Technology (NIST)

Related biology news :

1. Tough new spuds take on double trouble
2. Tigers in serious trouble around the world, including here in the US
3. Double trouble: Bacterial super-infection after the flu
4. Troublesome green algae serve as coating substrate in record-setting battery
5. Normal cells far from cancer give nanosignals of trouble
6. Tummy troubles -- gastrin key in bacterial-induced stomach cancer
7. Troubled waters: Low Apalachicola River flow may hurt gulf fisheries
8. Double trouble for water life
9. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
10. Penguins marching into trouble
11. Dry spells spelled trouble in ancient China
Post Your Comments:
Related Image:
Liposome-hydrogel hybrids: No toil, no trouble for stronger bubbles
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology: